Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Experimental Drug Prevents Ischemia in Mouse Muscular Dystrophy Model

By BiotechDaily International staff writers
Posted on 22 Nov 2012
Treating mice with a form of muscular dystrophy that closely mimics human Duchenne muscular dystrophy (DMD) with the experimental drug HCT 1026 restored normal blood flow to muscles stressed by a hormone-induced exercise regimen.

The dystrophin deficiency that characterizes DMD causes loss of the neuronal enzyme nitric oxide synthase from the sarcolemma, producing functional ischemia when the muscles are exercised. Investigators at Cedars-Sinai Heart Institute (Los Angeles, CA, USA) asked whether functional muscle ischemia could be eliminated and normal blood flow regulation restored by treatment with an exogenous nitric oxide (NO)-donating drug.

The drug under evaluation was HCT 1026, a NO-donating nonsteroidal anti-inflammatory agent that had previously been shown to slow progression of DMD in the mdx mouse muscular dystrophy model.

In the current study, beginning at eight weeks of age, mdx mice were fed a standard diet supplemented with 1% soybean oil alone or in combination with a low or high dose of HCT 1026. After one month of treatment, vasoconstrictor responses to intra-arterial norepinephrine (NE) were compared in resting and contracting hindlimbs.

Results published in the November 5, 2012, online edition of the journal PLOS ONE revealed that in untreated mdx mice, the usual effect of muscle contraction to attenuate NE-mediated vasoconstriction was impaired, resulting in functional ischemia. This NE-induced functional ischemia was unaffected by low dose HCT 1026 but was alleviated by the high dose of the drug. The beneficial effect of high dose HCT 1026 was maintained with treatment up to three months.

"There is an urgent unmet need for effective therapeutic options for this devastating disease," said senior author Dr. Ronald G. Victor, professor of cardiology at Cedars-Sinai Heart Institute. "If we can improve blood flow in muscular dystrophy patients, we may be able to preserve some muscle function over a longer period of time."

The authors stressed that they did not expect these novel nitric oxide-donating compounds to cure DMD, but did hope that the improved blood flow that they induced could reduce muscle fatigue and injury, allowing patients to be more active while slowing down the loss of vital muscle tissue.

Related Links:
Cedars-Sinai Heart Institute




Channels

Genomics/Proteomics

view channel
Image: Bacteriophage EFDG1 visualized by transmission electron microscopy (TEM) at a magnification of 20,000–30,000 times. Note that some phages are still bound to remains of the dead bacteria (Photo courtesy of the Hebrew University of Jerusalem).

Bacteriophage Therapy Eliminates Multidrug Resistant Bacterial Infections

Bacteriophage therapy has been shown to be an effective approach for treating infections caused by drug-resistant strains of the bacterium Enterococcus faecalis. E. faecalis, a bacterium inhabiting... Read more

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.